Florida Cancer Specialists & Research Institute introduces liquid biopsy test
Florida Cancer Specialists & Research Institute (FCS) in the US has introduced liquid biopsy, a blood test that rapidly identifies cancerous tumours and circulating cells in the bloodstream.
This test may be used to evaluate colorectal, lung, prostate, breast, and blood cancers.
Liquid biopsy represents an advancement in cancer diagnosis and treatment, utilising a simple draw of blood to test for circulating tumour DNA (ctDNA).
The introduction of liquid biopsy at FCS underscores the practice's focus on expanding its comprehensive genomic testing offerings, thereby improving diagnostic accuracy, guiding physicians in treatment decisions, and the patients' clinical outcomes.
FCS claims to have broadened its testing options for the 250 physicians serving more than 102,000 individuals across Florida, since the introduction of next-generation sequencing (NGS) offerings at its centralised in-house laboratory in 2021.
The practice has seen over 4.2 million annual visits and recently surpassed over 16,000 molecular tests processed at its Fort Myers lab facility.
FCS genetics laboratory associate director Jennifer Gass said: 'Liquid biopsy is especially effective for providing genetic information quickly for various types of advanced cancers to help physicians assess and better target treatments that may work best and monitor patient response.
'Additionally, because it is minimally invasive and easy to repeat on an ongoing basis, liquid biopsy is significantly more comfortable for patients.'
The expansion of the NGS testing menu at the FCS includes the addition of homologous recombination deficiency (HRD) testing, which analyses tumour DNA to determine potential treatment responses to poly (ADP-ribose) polymerase (PARP) inhibitors.
This class of drugs specifically targets cancer cells.
Other additions include a small heme NGS panel that identifies mutations related to myeloproliferative neoplasms and a quantitative assay for monitoring BCR-ABL gene fusions post-treatment in specific blood cancers.
"Florida Cancer Specialists & Research Institute introduces liquid biopsy test" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Scorpion, fresh off Lilly deal, spins out startup Antares
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Fresh off a multibillion-dollar deal with Eli Lilly, cancer drug startup Scorpion Therapeutics is trying for an encore, debuting a successor company on Tuesday that's carrying forward much of its previous work. Called Antares Therapeutics, the startup is launching with $177 million in financing from nearly a dozen investors, among them previous backers Omega Funds and Atlas Venture. Antares will use that cash to advance a group of small molecule drugs Scorpion had been working on, as well as programs the company had been advancing through a 2022 partnership with AstraZeneca. Its work will specifically focus on cancer and other unspecified 'serious diseases,' according to a statement. The company didn't divulge more details about its pipeline, only noting on its website that its first program should begin human testing in 2026 and multiple others are in preclinical development. In a statement, CEO Adam Friedman, who previously ran Scorpion, said the company's research is "fueled by discoveries in drugging previously inaccessible targets.' Antares could also get future milestone payments and royalties from a pair of cancer drugs involved in a Scorpion alliance with Pierre Fabre Laboratories. Another startup, Moma Therapeutics, has rights to a PARP inhibitor Scorpion was advancing, too. Scorpion was co-founded in 2020 by Gary Glick, who helped the company raise nearly $300 million in venture funding before departing in 2021. Prior to Scorpion, Glick led Lycera, which formed a 2015 deal with Celgene, and IFM Therapeutics, which has spun off multiple companies that were acquired by larger drugmakers. Glick went on to lead inflammatory drug developer Odyssey Therapeutics, which has been trying to go public. In the meantime, Scorpion was helmed by Friedman, who helped the company raise additional funding, form multiple partnerships and generate six cancer drug candidates, three of which are in clinical testing, according to its statement. Scorpion sold one, dubbed STX-678, to Eli Lilly in January for as much as $2.5 billion. As part of that deal, it formed a new company holding its other assets and inheriting its employees. That company, now known as Antares, is supported by Scorpion's old shareholders and also led by Friedman. 'Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,' said Keith Flaherty, a board member and director of clinical research at Massachusetts General Hospital Cancer Center, in a statement. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
10 hours ago
- Yahoo
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR
Delray Beach, FL, June 11, 2025 (GLOBE NEWSWIRE) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of the period. The genomics market is rising rapidly as advancements in NGS, long-read sequencing, and CRISPR expand genomics applications in precision medicine, diagnostics, drug discovery, and agriculture. This, in turn, is driving demand for genomic tools and services due to the increasing incidence of genetic disorders, cancer, and viral infections. Key players are investing in the development of more efficient and cost-effective solutions, making genomics increasingly accessible for both research and clinical settings. As personalized medicine and population genomics continue to gain momentum, the market is expected to grow globally. Download PDF Brochure: Browse in-depth TOC on 'Genomics Market'671 - Tables68 - Figures559 - Pages Based on offerings, the genomics market is divided into product and service segments. The product segment accounted for the largest share of the genomics market in 2023. This dominance is primarily attributable to the reagents, kits, and other consumables used in sequencing, PCR, and microarray technologies, which represent a major product category and contribute significantly to the market share. Advances in efficient and cost-effective sequencing technologies have also driven product innovation. As a result, genomics has become more accessible to a wider user base, including academic institutions, pharmaceutical companies, and healthcare providers. Product dominance in the genomics market is expected to continue due to its central role in enabling high-profile research and clinical advancements. However, the service segment accounted for the second-largest share in the market. Based on technology, the genomics products market is divided into sequencing, PCR, gene editing, flow cytometry, microarrays, in situ hybridization, and other technologies. Sequencing technology holds the largest market share in 2023, largely due to its extensive use in clinical settings for disease diagnosis, genetic testing, and personalized medicine, making it a dominant technology in the genomics market. The increasing demand for sequencing in research, particularly in population genomics, pharmacogenomics, and rare disease studies, fuels the growth of this segment. Continuing innovations in sequencing technology—including read lengths, accuracy, and automation—will drive expansion in genomics and reinforce the leading position of this segment. Based on product type, the market is segmented into reagents, kits, and consumables, instruments, and bioinformatics tools. The reagents, kits, and consumables segment accounted for the largest share of the genomics market in 2023. These consumables, used in sequencing, PCR, and microarray technologies, represent a major product category, contributing significantly to the market share. However, the instrument segment held the second-largest share within this category. Based on application, the genomics market is segmented into drug discovery & development, diagnostics, agriculture and animal research, and other applications. In 2023, drug discovery & development applications accounted for the largest share, mainly due to increased demand for genomics research in areas such as cancer, rare diseases, and population genomics. Genomics helps researchers study genetic variations and mutations that cause diseases, allowing them to better understand conditions such as cancer, neurological disorders, and infectious diseases. This opens new avenues for discovering more precise therapeutic targets. Pharmaceutical companies are increasingly using genomics to develop targeted therapies, which enhances the speed and accuracy of bringing new treatments to market, thereby contributing significantly to this segment. However, the diagnostics segment accounted for the second-largest market share. Based on study type, the genomics market is segmented into functional genomics, biomarker discovery, pathway analysis, epigenomics, and other study types. In 2023, the functional genomics segment accounted for the largest market share due to its importance in identifying potential drug targets, particularly in areas like cancer and genetic disorders, driving its widespread adoption in pharmaceutical research. The biomarker discovery segment held the second-largest market share. Based on end users, the genomics product market is segmented into hospitals, clinics and diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, CROs, and other end users. In 2023, the hospitals, clinics, and diagnostic laboratories segment held the largest share of the genomics market. This can be attributed to the increasing use of genomics in routine diagnostics and patient care—such as prenatal screening, oncology, and pharmacogenomics—which has made hospitals and clinics key users of genomics products. The genomics market is segmented into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America was the largest regional market for genomics in 2023, with Europe being the second largest. North America's large market share is attributed to the high prevalence of target diseases, which has increased the demand for cancer research and research into inherited rare diseases, along with government support. However, the Asia Pacific region is projected to be the fastest-growing segment, due to its large population and genomic initiatives aimed at studying genetic diversity and public health. Request Sample Pages : The global genomics market is competitive, with key players including Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Germany), Agilent Technologies, Inc. (US), Revvity (US), Laboratory Corporation of America Holdings (US), IQVIA Inc. (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc (UK), Takara Bio Inc. (Japan), BGI Group (China), Eppendorf SE (Germany), Merck KGaA (Germany), BD (US), Abbott (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Creative Biogene (US), Novogene Co., Ltd. (China), Helix, Inc. (US), Phalanx Biotech Group (US), and Polaris Genomics (US). Illumina, Inc. (US): Illumina is the market leader in commercializing genome sequencing solutions to help address questions about the functions of genetic variants and biological processes. To make the analysis of genetics easier, the company's product line includes consumables, integrated systems, and analytical instrumentation. Genomics products are offered through the equipment and consumables segment of the company. Genomics services are also offered through the Service and Other Revenue segment of the company. Stable investments that the company made in research and development helped the company to refine its portfolio along with the innovation to improve its accuracy and bring new uses. For instance, Illumina's first product from its proprietary Illumina Complete Long Read technology, was launched back in March 2023. Illumina Complete Long Read Prep, Human. Compatible with sequencing systems for high-performance, long-read human whole-genome sequencing on the following systems: NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. Thermo Fisher Scientific Inc. (US):Thermo Fisher Scientific Inc. is one of the leading providers of medical equipment, analytical instruments, reagents & consumables, software, and services. Through its Life Science Solutions segment, the firm operates in the genomics market. The company has a strong geographic presence across more than 100 countries. The company offers genomics products and services through the Genetic Sciences and Biosciences business. The company implements organic and inorganic growth strategies to support its business growth. For instance, in July 2043, the company launched the Novel Pre-transplant risk assessment assay, to assess the risk of kidney transplant rejection. Danaher Corporation (US):Danaher Corporation manufactures and commercializes medical, industrial, and commercial products and services. The company offers genomics products through its subsidiaries, Integrated DNA Technologies, Inc., Cepheid, Inc., and Beckman Coulter, which operates under the Life Sciences and Diagnostics segments. The company provides products & services to pharmaceutical and biotechnology companies, colleges & universities, research institutes, and government bodies (including government testing & diagnostic centers) through its sales and distribution offices network. The company spends on innovation and implements strategies such as product launches, partnerships, and collaborations. For instance, In May 2024, Integrated DNA Technologies, a subsidiary of Danaher, partnered with Molecular Health to integrate their NGS capabilities and to extend genomic profiling. For more information, Inquire Now! Related Reports: CRISPR Market Gene Editing Market Biomarkers Market NGS-based RNA-sequencing Market Artificial Intelligence in Genomics Market Get access to the latest updates on Genomics Companies and Genomics Market Size CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Molecular Oncology Diagnostics Research Report 2025 - Global $7.84 Bn Market Trends, Opportunities, and Forecasts, 2020-2030: AI and Machine Learning Driving Double-Digit Growth
The Molecular Oncology Diagnostics Market is set for significant growth, driven by increased cancer incidence and demand for early detection. Opportunities include advancements like next-generation sequencing, AI integration for faster data analysis, and personalized medicine. Challenges remain with high costs and accessibility, but policy support and innovation may bridge gaps. Molecular Oncology Diagnostics Market Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Molecular Oncology Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Molecular Oncology Diagnostics Market was valued at USD 3.54 Billion in 2024, and is expected to reach USD 7.84 Billion by 2030, rising at a CAGR of 14.17% The market is expanding rapidly due to the rising incidence of chronic diseases, particularly cancer, which is driving the demand for advanced diagnostic solutions. Molecular oncology diagnostics refer to specialized tests used to detect cancer at the molecular level, identifying genetic materials, proteins, and biomarkers that signal the presence of disease. This approach supports early detection, targeted therapy, and improved patient outcomes. Increased awareness, advances in technology such as next-generation sequencing (NGS), and growing investments in personalized medicine are all contributing to market growth. In addition, stringent regulatory frameworks and a global shift toward precision oncology are encouraging innovation in molecular diagnostic platforms. As healthcare systems worldwide emphasize early detection and efficient disease management, the molecular oncology diagnostics market is poised for sustained expansion across developed and emerging Market Drivers Increasing Global Cancer Incidence and Demand for Early DetectionThe rising global prevalence of cancer is a major factor propelling growth in the molecular oncology diagnostics market. According to the World Health Organization (WHO), nearly 10 million people died from cancer in 2020, with the incidence rate expected to rise by 47% by 2040, reaching over 28 million new cases annually. This alarming increase has led to a heightened focus on early detection and precision diagnostics to improve treatment outcomes and reduce healthcare burdens. Molecular diagnostics offer a pathway for identifying cancer-related mutations, chromosomal changes, and gene expression profiles even before clinical symptoms like PCR, NGS, and microarrays are pivotal in enabling personalized treatment strategies and enhancing prognosis accuracy. Governments and research bodies are investing heavily in cancer diagnostics infrastructure; for example, the U.S. National Cancer Institute allocated over $7 billion in 2023 for cancer research, with a strong emphasis on molecular diagnostic tools. These developments underscore the growing importance of molecular oncology diagnostics in combating the global cancer Market Challenges High Cost and Limited Accessibility of Advanced Diagnostic TechnologiesDespite technological progress, the high cost of molecular oncology diagnostics remains a critical barrier to widespread adoption. Advanced testing methods like next-generation sequencing and multiplex PCR panels require expensive reagents, equipment, and skilled professionals, making them inaccessible in many low- and middle-income countries. A single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems. Furthermore, insufficient diagnostic infrastructure, particularly in rural areas, exacerbates disparities in healthcare include a lack of molecular pathology labs, inadequate cold chain systems, and a shortage of trained personnel. Even in developed nations, inconsistent reimbursement policies hinder the adoption of newer molecular tests. According to the World Bank, healthcare expenditure in low-income nations averages about 5% of GDP, compared to more than 10% in high-income countries. This disparity underscores the urgent need for policy support, public-private partnerships, and cost-reduction strategies to bridge the accessibility gap in molecular Market Trends Integration of Artificial Intelligence and Machine Learning in Molecular DiagnosticsA transformative trend in the molecular oncology diagnostics market is the integration of artificial intelligence (AI) and machine learning (ML) technologies to streamline and enhance genomic data analysis. As diagnostic platforms generate increasingly complex datasets, AI and ML provide tools to analyze patterns, classify cancer subtypes, and predict patient responses more accurately and rapidly than manual technologies can process thousands of variants simultaneously, identifying clinically relevant mutations and helping in treatment selection. Deep learning models are also being used to enhance the accuracy of image-based diagnostics and to interpret multi-omics data in real-time. Governments are supporting AI development through major funding initiatives, such as the NIH's Bridge2AI program in the U.S. and the UK's Industrial Strategy Challenge Fund. These efforts are catalyzing the adoption of AI-driven diagnostics, making molecular oncology testing more efficient, scalable, and accessible across the Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.54 Billion Forecasted Market Value (USD) by 2030 $7.84 Billion Compound Annual Growth Rate 14.1% Regions Covered Global Report Scope: Competitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market. Sysmex Corporation F. Hoffmann-La Roche Ltd. Myriad Genetics, Inc. HTG Molecular Diagnostics, Inc. Danaher Corporation QIAGEN N.V. Bio-Rad Laboratories, Inc. Agilent Technologies, Inc. Illumina, Inc. Bayer AG Molecular Oncology Diagnostics Market, By Product Type: Instruments Kits and Assays Software Molecular Oncology Diagnostics Market, By Technology: Fluorescence In-Situ Hybridization (FISH) Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Immunohistochemistry (IHC) Flow Cytometry Other Technologies Molecular Oncology Diagnostics Market, By Application: Research Clinical Molecular Oncology Diagnostics Market, By Cancer Type: Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors) Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies) Molecular Oncology Diagnostics Market, By End User: Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes Molecular Oncology Diagnostics Market, By Region: North America United States Mexico Canada Europe France Germany United Kingdom Italy Spain Asia-Pacific China India South Korea Japan Australia South America Brazil Argentina Colombia Middle East and Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Molecular Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
